Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips News that Cocrystal Pharma (NASDAQ: COCP ) has made progress on its Covid-19 antiviral drug candidates and plans to expand development has sent the COCP stock price up more than 40% in Tuesday’s pre-market trad...
BioLineRx (BLRX) +62% on positive top-line results from GENESIS phase 3 trial.Cocrystal Pharma (COCP) +40%.Huttig Building Products, Inc. (HBP) +26% on Q1 results.Vaxart (VXRT) +20% as its oral COVID-19 vaccine shows potential to offer promising solution against variants.Precip...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning and welcome to another busy day of trading on the stock market. We’re keeping up with the latest trading trends as we check out the biggest pre-market stock movers for Tuesday morning. Source: Eric U...
Cocrystal Pharma (COCP) announces progress in developing broad-spectrum antiviral drug candidates that COVID-19. In December 2020, Cocrystal selected CDI-45205 as its lead coronavirus development candidate under an exclusive license agreement with Kansas State University Research Foundation. ...
Brooklyn ImmunoTherapeutics (BTX) +38%.Regional Health Properties (RHE) +21%.Gaucho Group Holdings (VINO) +15%.Ashford Hospitality Trust (AHT) +15%.Ocugen (OCGN) +13% as COVAXIN demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2, B.1.128.2.DAVIDsTEA (DTEA) +10%...
BOTHELL, Wash., May 03, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machiner...
The FDA approval process for vaccines, therapeutics, and other pharmaceuticals was on the nightly news through late 2020. Investors and non-investors alike developed some understanding of that FDA timeline. Medical device clearance is less understood yet critical for investors looking to benef...
Gainers: Bonso Electronics International (BNSO) +36%.SOS (SOS) +29%.Ouster (OUST) +29%.ION Geophysical (IO) +22%.Odonate Therapeutics (ODT) +20%.Titan Medical (TMDI) +16%.Cocrystal Pharma (COCP) +15%.Ocugen (OCGN) +15%.Pintec Technology (PT) +13%.Frequency Therapeutics (FREQ) +...
Cocrystal Pharma (COCP): FY GAAP EPS of -$0.17 beats by $0.03.Revenue of $2M (-69.5% Y/Y) misses by $0.08M.Shares +0.63% PM.Press Release For further details see: Cocrystal Pharma EPS beats by $0.03, misses on revenue
Outlines 2021 product pipeline milestones for COVID-19, influenza A and norovirus antiviral programs Ends 2020 with cash exceeding $33 million and a clean capital structure BOTHELL, Wash., March 17, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), ...
News, Short Squeeze, Breakout and More Instantly...
Cocrystal Pharma Inc. Company Name:
COCP Stock Symbol:
NASDAQ Market:
Cocrystal Pharma Inc. Website:
BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) today reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of the Phase 1 study in healthy volunteers wit...
BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc .’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A (H5N1) PB2 protein recently identified in infected dairy cattle, according to recently ...
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 Enrollment completed in Phase 2a influenza A human challenge study of oral CC-42344, with topline results expected ...